RO 5469754

Drug Profile

RO 5469754

Alternative Names: RO-5469754

Latest Information Update: 19 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Unspecified

Most Recent Events

  • 19 May 2016 No recent reports of development identified - Phase-I for Undefined indication in Netherlands (SC & IV)
  • 01 Nov 2012 Roche completes a phase I trial in Healthy volunteers in Netherlands (NCT01620931)
  • 15 Jun 2012 Roche completes enrolment in its phase I trial in Healthy volunteers in Netherlands (NCT01620931)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top